Across TCGA pan-cancer cohorts, RYR2 Mutation is linked to patient survival in 19 of 34 cancer types, making it a survival-associated RYR2 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher RYR2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RYR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.
KIRP, UCEC, and BLCA are the cancer types where RYR2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.